Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Key Points

• The aim is to determine the survival benefits of adding bevacizumab to standard chemotherapy for non-small-cell lung cancer.
• Randomized trial involving selected patients with non-small-cell lung cancer.
• Patients received either paclitaxel plus carboplatin alone or with bevacizumab.
• Clinical trial registered under NCT00021060.
• Bevacizumab addition resulted in significant improvement in survival.
• Increased risk of treatment-related deaths was associated with bevacizumab.